Archive · 14 Jan 2026
Dr Reddy’s Launches First Generic Pataday Extra Strength in US
Dr Reddy’s Laboratories, a big pharma company, has launched a generic version of the popular Pataday Extra Strength eye drops in the US.
This is the first time a generic version of this product is available.
The eye drops help with itchy eyes caused by things like pollen and animal hair.
The company already sells lower-strength versions of the same medicine.
They are excited about this new product and think it will help them work better with their retail customers.
The original Pataday brand made about $70 million in sales last year.
The company’s stock price went up a tiny bit after this news.
Dr Reddy’s Laboratories launched the first generic version of Pataday Extra Strength eye drops in the US.
The generic version is sold as olopatadine hydrochloride ophthalmic solution USP 0.7%, approved by the FDA.
The eye drops provide temporary relief from itchy eyes caused by allergens like pollen and animal dander.
This launch expands Dr Reddy’s existing US OTC eye-care portfolio, which includes lower-strength versions of olopatadine.
The company’s Pataday brand recorded US sales of about $69.9 million in 2025.
- Who
- Dr Reddy’s Laboratories Ltd
- What
- Launched a generic version of Pataday Extra Strength eye drops
- When
- Wednesday, 2025
- Where
- United States
- Why
- To expand its OTC eye-care portfolio and provide a generic alternative for itchy eyes relief
- Company
- Dr Reddy’s Laboratories Ltd
- Product
- Generic version of Pataday Extra Strength eye drops
- Active Ingredient
- Olopatadine hydrochloride ophthalmic solution USP 0.7%
- Regulatory Approval
- US Food and Drug Administration (FDA)
- Market Position
- First generic version in the US
- Existing Portfolio
- Lower-strength olopatadine versions (0.1% and 0.2%)
- Brand Sales
- $69.9 million (2025)
- Stock Price
- ₹1,191.50 (January 14, 2025)
